Summary: T-cell mediated immunotherapy for malignant diseases has become an effective treatment option, especially in malignant melanoma. Recent advances have enabled the transfer of high T-cell numbers with high functionality. However, with more T cells becoming technically available for transfer, questions about dose, treatment schedule, and safety become most relevant. Mathematical oncology can simulate tumor characteristics in silico and predict the tumor response to novel therapeutics. Using similar methods to classical pharmacokinetics/pharmacodynamics-type models, mathematical oncology translates the findings into a multiparameter model system and simulates T-cell therapy for malignant diseases. The tumor and immune system dynamics model can provide minimal requirements (in terms of T-cell dose and T-cell functionality) depending on the tumor characteristics (growth rate, residual tumor size) for a clinical study, and help select the best treatment schedule (repetitive doses, minimally required duration, etc.). Here, we present a new mathematical model developed for modeling cellular immunotherapy for melanoma. Computer simulations based on the new model offer an explanation for the observed finding from clinical trials that the patients with the smallest tumor load respond better. We simulate different parameters critical for improvement of cellular therapy for patients with high tumor load of fast-growing tumors. We show that tumor growth rate and tumor load are crucial in predicting the outcome of T-cell therapy. Rather than intuitively extrapolating from experimental data, we demonstrate how mathematical oncology can assist in rational planning of clinical trials.
A doptive immunotherapy using tailored T-cell infusions to treat malignancies has been proven to be effective in certain types of malignancy.
1,2 However, our understanding as to why certain patients respond whereas others progress, is still limited. Moreover, clinical approaches using T-cell therapy still vary widely in issues such as how to generate large numbers of specific T cells, how many T cells to use for therapy, and what schedule would be most effective. The expansion of tumor-specific T cells have been hindered by the often low-precursor frequency in patients or healthy individuals, the loss of high-affinity T cells during ex vivo culture and the terminal differentiation of extensively cultured and expanded T cells, resulting in loss of function and persistence upon transfer to the patient. 3 Recently, progress has been made with genetic engineering of chimeric antigen receptors, T-cell receptor transfer, and silencing of genes exerting unfavourable functions. 4, 5 Furthermore, use of new cytokine combinations allows the rapid expansion of less differentiated T cells with an enhanced functional capacity. 6 However, recent preclinical and clinical data also reveal the dangers of this type of therapy with several serious adverse events related to T-cell infusions being reported. [7] [8] [9] Therefore, with high numbers of antigen-specific T cells becoming available for clinical use and at the same time considering the potential risks, we asked, whether rather than intuitively deciding on a given T-cell regimen, mathematical modeling would help to define the prerequisites of an effective immunotherapy approach.
Integrative mathematical oncology is widely used to decode the cancerous process. 10 Several, mechanistic or descriptive, models have been proposed to better understand the growth dynamics of cancerous cells embedded in the nonmalignant environment. Part of the models has studied 3-dimensional growth of tumors, whereas others have preferred the use of nonspatial mathematical models. 11, 12 In this context, modeling tumor-immune interactions has been key issue over the past 2 decades. De Boer et al 13 were one of the first to model the interaction between T cells, macrophages, and tumor cells, taking into account a variable immunogenicity of the tumor cells. In this in silico model, small variations in specific T-cell subsets, especially the number of activated helper T cells, had a large impact on tumor cell growth, whereas calculated required number of cytotoxic T cells to achieve the same effect was 1000-fold higher. However, Takayanagi and Ohuchi 14 provided mathematical analysis showing that an increased number of cytotoxic T cells may ultimately tilt the balance between tumor and immune system in favor of the latter. Other groups have investigated different aspects of immunotherapy such as the role of tumor dormancy, the therapeutic use of interleukin-2 (IL-2) and the effects of tumor-associated cytokines such as transforming growth factor b (TGFb) or epidermal growth factor. [15] [16] [17] [18] [19] For a comprehensive review of simulation methods of tumor immunology see Woelke et al. 20 We recently developed a mathematical model of T-cell therapy for glioblastoma that includes the mutual interactions between the immunosuppressive tumor and the expression of major histocompatibility complex (MHC) receptors, which can be induced by cytotoxic T-lymphocyte (CTL)-secreted cytokines. 21 The mathematical model, furthermore, predicts the existence of a threshold value of T-cell infusion rate, which needs to be crossed, before a significant impact on the tumor growth can be observed. 22 In this study, we present a mathematical model for immunotherapy in the context of published clinical data. We chose immunotherapy by transfer of ex vivo expanded tumor-specific T cells for melanoma patients, as this therapeutic strategy has been shown to be especially effective in this patient population. At the same time, little is known about the actual numbers of T cells required for therapeutic treatment, resulting in a wide variation in T-cell numbers across clinical studies. In fact, T-cell dosing is often calculated based on body surface area-a concept, which stems from pharmacological substances which rely on renal excretion-or on body weight, rather than on the estimated tumor burden. However, this is exactly where mathematical modeling may help to design an individualized treatment schedule for each patient. On the basis of reported parameters in the literature, a mathematical model was built by transferring a descriptive model into mathematical equations. Using experimental quantitative data reported recently, the model was then retrospectively validated. We then analyzed treatment schedules used previously in clinical trials, to assess the magnitude of a functional T cells response required to efficiently target malignant melanoma. We show that even high T-cell numbers used for therapy will unlikely influence large and fast-growing tumors, unless the functional capacity of each T-cell product is improved. Furthermore, finer quantification of residual tumor load may assist in identifying patients, which will benefit from this type of therapy.
METHODOLOGY
In our previous study, 21 a simplified mechanism for alloreactive cellular therapy for glioblastoma was introduced. Partially, based on this previous study, we developed a new model with special adaptation to melanoma and melanoma immunotherapy parameters. Figure 1 shows a scheme of the model. The mathematical equations are:
Mathematical Equations
.
Equation (1) describes the tumor cell, T, dynamics, (the dot is the time derivative), as influenced by tumor cell maximal number, K, CTL population, C, killing efficacy of the CTLs, a T , presence of MHC class I receptors, M I , and the level of TGFb secretion. For full explanations here and hereafter and list of parameters see Appendix, Supplemental Digital Content 1, http://links.lww.com/JIT/A157.
Equation (2) describes the dynamics of the CTLs, C, by the death rate of CTLs proportional to the population of CTLs, with coefficient m C , and finally I, the CTL infusion rate.
Equation (3) describes the dynamics of TGFb, F b , as proportional to the tumor cell population, T, with a b,T , as a proportion coefficient and is destroyed at a rate of m b proportional to F b .
Equation (4) describes the dynamics of IFNg, F g , as proportional to the population of CTLs, C, with proportion coefficient, a g,c , and is destroyed at a rate m g proportional to the amount of F g .
Equation (5) describes the dynamics of MHC class I molecules, M I, are presented on the tumor cell surface at a rate g MI, this rate is augmented by a Michaelis-type term dependent on F g . The M I molecules are internalized at a rate m g.
Model Assumptions
The current model assumes that a primary tumor cell population and a metastatic tumor cell population are indistinguishable by size alone or level of malignancy per metastatic population. We feel it is a safe assumption to make for most of the patients, at least at this fundamental stage of model development. 
COMPUTER SIMULATIONS
Computer simulations were performed using Matlab. For all computer simulations, tumor initial population size was determined between 1 Â10 10 to 5 Â10 11 cells. We divided this range into 50 equal intervals. Tumor growth rates were set between 0.0001 to 0.01/hour. In the same manner that range was divided into 10 equal intervals. All combinatorial possibilities were then crossed, creating 50 Â 10 = 500 combinations of tumor initial population size and tumor growth rates. The crossing imitates a virtual population of patients with a wide range of personal disease characteristics. Computer simulations predicting tumor population size under different adoptive T-cell therapy regimens over 300 days were run with these initial conditions. Of this 500 virtual patients' grid (or data set), 100 patients were selected randomly and their simulation results were presented in plots and summary statistics. The results of randomly selected 100 patients were plotted.
Clinical Interpretation of Computer Simulation Results
Response Evaluation Criteria in Solid Tumors are being adopted in many clinical studies to help harmonization of data analysis for clinical outcome. 23 We adopted these criteria for the definition of progression/nonresponders (larger than 120% of original size), stable disease (70% to 120%), and partial (30% decrease) or complete response (disappearance).
RESULTS

Description of the Model
This mathematical model simulates the effect of cytotoxic lymphocytes on melanoma cells (Fig.1 ). It consists of 5 differential equations describing the dynamics of the tumor growth, CTL persistence, cytokine secretion, and MHC class-I expression. The exact dynamics is controlled by the following key parameters: cytolytic activity of the T cells, tumor growth rate, survival of the T cells, and the collective sensitivity of the tumor cells to killing (h T ). It is a refined model of our previous study modeling immunotherapy for glioblastoma patients. 21, 22 A detailed description of the model and all the relevant parameters is given in the Appendix, Supplemental Digital Content 1, http://links. lww.com/JIT/A157.
Selection of Studies Simulated With This Model
We wanted to simulate 4 representative immunotherapy studies based on the data obtained from published literature to model the greatly varying treatment schedules and results. [24] [25] [26] The 4 studies were selected using the following criteria: clinical trials (phase I/II) using antigenspecific T cells to target malignant melanoma; data available in the literature to model treatment schedule in terms of dose and timing; different research groups with only 1 study per group. The 4 selected studies are summarized in Table 1 illustrating the significant variation in terms of T-cell numbers administered, frequency of infusions, and initial tumor load. Therefore, these main factors were analyzed with this model.
Polyclonal T-cell Lines in Stage III Melanoma
Khammari et al 24 compared infusions of ex vivo expanded tumor infiltrating lymphocytes (TILs) with IL-2 versus IL-2 treatment alone. Eighty-eight patients were enrolled and equally distributed into each arm of the study. These patients had not received earlier systemic treatment and were enrolled when regional lymph node recurrence occurred after surgery (stage III, T1-4N recurrent M0). The group reports on a long follow-up of more than 10 years.
Patients with 1 invaded lymph node were compared with patients with multiple lymph node metastasis. Patients with only 1 invaded lymph node receiving TIL and IL-2 had a striking survival advantage over patients receiving IL-2 only (33.3% vs. 68.42% relapse percentage). This difference was not seen in patients with multiple lymph node metastases, suggesting that tumor load impacts efficacy of the treatment. Tumor load and tumor growth rate for each individual patient, however, are not reported in the study. 21, 22 To model this study, we therefore chose a range of initial tumor sizes and tumor growth rates (see Methodology section for details) and simulated the potential outcome for 500 different combinations of initial tumor load and growth rate values (Fig. 2) . In analogy to the clinical protocol, we simulated a treatment regimen with 2 infusions given 1 month apart. Simulations were performed using the reported median cell dose of 1.7 Â10 10 , Fig. 2C ) doses. As the best reported value of tumor specific T cells was 13.8%, T-cell dose was corrected for 10%.
Simulated response rate (all the patients but the nonresponders) varied between 1% and 25% (Figs. 2B, C) depending mainly on TIL dose. However, even with the highest T-cell dose, and assuming favorable conditions for the T cells, only tumors with the lowest size could be delayed significantly in their growth or reduced in size reflecting complete remission according to Response Evaluation Criteria in Solid Tumors' criteria. Thus, the mathematical model predicts that repetitive lysis of tumor cells by each T-cell infused, results only in rare circumstances, such as low residual tumor size, in a significant impact on the tumor.
The fact that only patients with involvement of a single lymph node showed a benefit in this study, suggested a quantitative effect of the T cells in the tumor load. However, in a subgroup analysis of the 27 patients for whom data on the content of tumor-reactive T cells were available, no correlation was found between clinical outcome (as indicated by relapse vs. no relapse) and the applied dose of antigenspecific T cells. 28 One likely explanation may be the small sample size. Computer simulation offers an alternative explanation: Figure 3 , no correlation can be seen between outcome (final tumor size) and initial tumor volume, regardless of the T-cell dose infused. This is in line with the clinical observation. Only when the initial tumor burden is sufficiently small, a dose-effect relationship of the T cells can be established, suggesting that rather than clinical staging as was done in this trial, a detailed volumetric analysis of residual tumor masses-if at all possible-may represent better correlation with clinical effectiveness of a T-cell response. TIL dose-effect relationship can be seen only for small initial tumor size and completely vanishes for large initial tumor cell numbers (Fig. 3) .
T-cell Clones With Defined Specificity
The exact fraction of antigen-specific T cells within the infused T-cell lines remained unknown in the study by Khammari et al. 24 To address better the actual number of antigen-specific T cells, we simulated a different study, in which clonally expanded antigen-specific T cells, thus suggesting similar tumor reactivity, were used. 26 Ten stage IV melanoma patients (metastatic disease) were treated with 3.3 Â 10 9 /m 2 CTLs given in biweekly infusions 4 times-with 2 patients receiving 6 and 7 infusions respectively, and 2 patients receiving only 3 infusions. Detailed data on initial tumor burden are not available. Yee et al's 26 clinical data report on 7 of 10 patients as having partial responses, 5 of which reaching stable disease with a mean duration of approximately 1 year and 2 patients with progressive disease. Mathematical modeling suggests a 59% response rate (complete and partial responses) at 300 days posttreatment (Fig. 4) . Bearing in mind that the actual tumor burden or tumor growth rates of the patients were not available, the agreement between the clinical trial and the simulations is good. The number of antigen-specific T-cell numbers of each infusion in Yee et al's 26 trial was comparable to the highest T-cell dose infused in the Khammari study; however, 4 infusions were given in Yee et al's study as opposed to 2 infusions in the Khammari trial. This may account for the higher response 
Multiple Infusions With Short-term Cultured T-cell Lines
To address the question, how the number of infusions affects treatment success, we chose a study performed by Mackensen et al. 25 Polyclonal T-cell lines were generated against a single epitope (MelanA/MART1) and infused (average: 2.1Â 10 8 T cells). Three T-cell infusions were scheduled 2 weeks apart, followed by up to 10 infusions in 4-week intervals. IL-2 was administered for 6 days after each infusion. Eleven patients were treated. 25 One patient achieved a complete response and 1 patient achieved partial response; 2 others had stable disease and mixed reactions. Computer simulations of randomly selected virtual patients showed a positive response rate of 10% (at day 300 posttreatment), which is lower than the reported clinical data (36%, 3 mo minimal observation time) (Fig. 5A) . Next, we used the model to search for more effective regimens, which were not observed in Mackensen clinical trial. Figure 5B shows that all other parameters being equal, increasing the T-cell dose to 5 Â10 8 cells (which is still 10 times less than the dose apllied in Yee et al 26 ) increases response rates within the simulation to 20%. When T-cell mediated tumor lysis parameter was increased 2-fold (Table 1 in Supplemental Appendix, Supplemental Digital Content 1, http://links.lww.com/JIT/A157 ), a positive effect was observed on 24% of the simulated patients (Fig. 5C ) combining higher lytic capacity and increased T-cell dose lead to a greatly increased efficacy of 34% (Fig. 5D ).
Excessive T-cell Numbers Combined With Chemotherapy
Whereas experimentally it is possible but difficult to assess differences in lytic capacity between different clinical studies, due to differences in handling the T cells and performing the assays, T-cell numbers are more comparable. A correlation between cell numbers and clinical efficacy was already established with the aforementioned simulations. However, the magnitude of the T-cell dose needed to achieve durable responses in most of the patients was unclear. We therefore analyzed data of a clinical trial performed by Steve Rosenberg group, in which a very high number of T cells were used-in fact, to the best of our knowledge, it is the highest number of T cells used and reported for adoptive T-cell therapy. 27, 29 These studies have used nonmyeloablative chemotherapy before the TIL infusion. A total of 1 Â10 11 cells were given in 1 bolus infusion and more importantly total body irradiation (TBI) therapy in a low dosage (2 Gy) and in high dosage (12 Gy) was added to the therapy. 29 The positive response rate was 13 of 25 (52%) and 18 of 25 (72%), respectively. In the simulations we show here, we chose to simulate the highdose treatment assuming antigen specificity of 10% based on Table 3 in Dudley et al's study. 29 When this high dose was given alone, a positive response in 52% of the patients 3 . Predictions of the final tumor cell number as a result of TIL dosage according to data derived from Khammari et al. 24 One hundred virtual patients were simulated as in Figure 2 except that TIL dose was also randomly chosen from 5 different dosages between 0.11Â 10 10 to 1.35Â 10 10 , given twice, 1 month apart. Upper illustration shows simulated treatment results using the lowest TIL dose, middle illustration shows simulated results using intermediate TIL dose (0.73Â 10 10 ), and lower illustration shows simulated treatment results with the highest TIL dose. Red dashed line delineates the separation between responsive tumor sizes to its left, and nonresponsive tumor sizes to its right. TIL indicates tumor infiltrating lymphocyte.
was predicted (Fig. 6A) . Next, we simulated a possible effect of low intensity TBI immediately before the TIL infusion. We assumed that such a treatment could decrease tumor load. Figure 6B shows that reducing tumor load by 10% increased positive responses to 56%. To simulate the high TBI treatment, we assumed that in addition to tumor size reduction, the high dose TBI sensitizes tumor cells to CTLmediated lysis (eg, by an increase in tumor accessibility due to proinflammatory signals). Such a change in the tumor-CTL accessibility is reflected in the parameter, h T . A simulated increase of 33% results in a similar positive response in 71% of the virtual patients (Fig. 6C) . The accessibility parameter h T is used in modeling tumor-immune interactions to attenuate the killing efficacy of CTLs as the tumor increases (for instance de Pillis et al 30 ) . Of all parameters used, it is the most difficult parameter to assess experimentally, as multiple events leading to a potential increase in sensitivity of the tumor cells for T-cell-mediated lysis may be represented by this parameter (eg, the elimination of regulatory T cells). However, it is a valid alternative explanation to increased efficiency of T-cell immunotherapy through a general effect on tumor sensitivity due to the preparative chemotherapy/radiotherapy, which results in higher response rates.
DISCUSSION
This new mathematical model, simulating 4 independent clinical trials, emphasizes 3 critical issues for this type of therapy: (1) cellular therapy is based on the functional capacity of each individually transferred cell; (2) even high T-cell numbers used for therapy will unlikely influence large and fast-growing tumors; and (3) the current classification of tumors (stage and grade) needs to be refined for proper estimation of the residual tumor cell mass. Future model modifications may include classification of tumors by the metastatic sites and their malignancy scores. Currently, we feel, however, that even population size alone can provide us with ample insights and predictions as to the success of T-cell therapy.
Absolute tumor burden and growth dynamics can be estimated within a certain degree of certainty at the start of cellular therapy taking into account size, stage, and grade of the tumor. As demonstrated here, low initial tumor cell mass is critical for the success of T-cell therapy. For instance, although Mackensen et al 25 do not report exact tumor burden, it is hard to ignore the fact that all patients that showed any response at all (mixed, partial, or stable disease) were the ones with only one disease site ( Table 1 in Mackensen et al study), which is consistent with Khammari's findings. This underlines the importance of quantitative effects in cancer progression and the existence of a window of opportunities for efficacious treatment.
In the simulations presented here, both tumor cell numbers and growth rates were randomly chosen within a preset range to simulate various biological preconditions. This hands-on way of simulating variable and parameter ranges is uncommon in mathematical articles modeling immunotherapy. However, we believe such simulations are closer to the clinical situation, and this way of presenting mathematical modeling may be more tangible for physician scientists. This model is based on the assumption that T cells lyse tumor cells repetitively throughout their life span. Therefore, it is logical that a T-cell dose effect will be observed, but the extent of this effect could not be foreseen. However, what is becoming evident by mathematical modeling and computer simulation is the degree to which cellular therapy needs to be augmented to expect a significant impact. The data clearly illustrates the quantitative effects for clinical trials: the T-cell dose ranged throughout all 4 studies from 1 Â10 8 to 1 Â10 11 T cells. Assuming the lytic activity of the cells being equal, there was little chance of a tumor response using Mackensen's approach, whereas the use of a 1000 times higher T-cell dose combined with synergistic measures (such as TBI before therapy) increased the likelihood of a response significantly. Delving deeper into Dudley et al's 29 data the percentage of CD8 + cells of TILs is consistently higher for responders than for nonresponder patients (82.1% vs. 74.9% in the 2 Gy treatment, and 86.0% vs. 60.5% in the 12 Gy treatment). When comparing the percentage of specific Mart-1 of CD8 + cells, we find the same trend as before, as responder patients were administered with a higher percentage of Mart-1 cells (19.6% vs. 3.4% in the 2 Gy treatment, and 2.8% vs. 1.6% in the Gy treatment). Therefore, the responder patients clearly received higher dosage of effective Mart-1 cells. Therefore, taking a mechanistic view of the T-cell effect, the broad range alone can explain success or failure of the respective regimen. This model allows for the first time to compare unrelated studies with immensely varying treatment schedules.
Very little data is available on the exact numbers required for an efficient immune response against tumor antigens. As shown in Figure 3 , simulation suggests the existence of a threshold of T-cell dose that has to be crossed before an effect on the tumor can be observed. The existence of such a threshold in a tumor T-cell therapy type of system was predicted by Kogan et al. 22 Its clinical meaning is that the high renewal potential of the tumor renders any trial to just reduce the tumor and keep it in check, futile. Unless the tumor is eradicated, no long-term stable equilibrium can exist. If the doses used are just below and above the threshold, this effect will be most striking in the smallest tumors as can be seen in Figure 3 . In a recent study by Budhu et al, 31 the efficiency of T-cell-mediated killing has been carefully correlated with the T-cell concentration. It is shown that the efficacy of such killing significantly increases, once the T-cell dose is beyond a certain threshold. In Budhu et al's study, it is demonstrated that-in an in vitro setting-a ratio of 1000:1 to 10:1 of effector-to-tumor cells ensures the elimination of a tumor cell population of 1 Â10
4 to 1Â 10 6 , respectively. When the researchers incubated melanoma B16 cells with T cells at roughly 1:1 ratio for 7 days in the presence of IL-2, they received nearly 100% killing. Without the presence of IL-2, the researchers required a 20:1 ratio to achieve tumor eradication and the functionality of the T cells lasted for only 5 days. A distinct threshold value of T cells is apparent below which the effect of T-cells is very weak and above which it is dramatic (Budhu et al 2010, Fig. 5 ). The existence of a numerical threshold effect has recently been predicted in a mathematical analysis of the immunotherapy for treatment of glioblastoma. 22 Such stepwise function of immunotherapy is counter intuitive for the physicianalthough not entirely unfamiliar when thinking of pharmacokinetics and pharmacodynamics. Identifying this step on the basis of mathematical modeling may increase the success rate of cellular immunotherapy.
In a clinical setting, a T-cell dose in the order administered by the Rosenberg group (1 Â10 11 ), which may be called a supraphysiological T-cell dose, may induce a cytokine storm-with release of interferon-g, IL-8, tumor necrosis factor-a etc. Ultimately, the inhibitory milieu of the tumor environment might be overcome, leading to upregulation of MHC class-I expression on the tumor cells and consequently increased tumor cell lysis.
In summary, mathematical modeling holds the promise that immunology-and especially human immunology-is not just a black box, where the effects of a certain treatment are unpredictable, but that before a clinical trial the interplay between crucial parameters can be analyzed and predicted. The model is dependent on quantitative data: some of the parameters implemented in the model are deduced from diverse sources. The accuracy of model prediction can be improved, when such quantitative data are available for each individual study. It seems therefore necessary to raise the awareness of cellular therapists for the potential of mathematical modeling and improve the quality of quantitative data.
But even without exact data on tumor size and growth rate, we tried to account for biological variability by allowing a range of initial tumor sizes and growth rates. The efficacy of the T cells-being regarded as "serial killers" in this model-may be lower than the values used for simulation, thus, if anything, required T-cell doses would even be higher.
Proliferation of tumor-specific T cells may be crucial to solve the need for large amounts of T cells as simulated in this study. The proliferative capacity of antigen-primed T cells depends on the differentiation state: late stage effector cells have a good lytic capacity but poor proliferative capacity and little in vivo persistence, whereas early effector memory T cells or central memory T cells have the capacity to further expand in vivo. Exciting new studies point toward differentiation pathways that can be manipulated ex vivo to maintain or induce a central memory phenotype, thus increasing the persistence, functionality, and the potential efficacy of such T cells. [32] [33] [34] Biomathematical modeling of T-cell immunotherapy has its greatest value, when sufficient numbers of T cells are available. In fact, we recently calculated for a glioblastoma model, that-technical challenges aside-a constant rate of T-cell infusions directly into the tumor bed over a prolonged time (weeks) may defeat even large tumors 22 ; such regimen also avoids peak T-cell load. Mathematical modeling can also predict the minimum number of T cells needed to have a reasonable chance to have an impact onto the residual tumor masses. In other words, mathematical modeling can provide the order of magnitude of the T-cell treatment required.
We are aware of the technical challenges of generation and application of such large numbers of antigen-specific T cells. However, for some antigens such as Melan-A, using improved protocols, the T cells can already be expanded to very high numbers within a short culture time, 6 or-for antigens with a lower T-cell precursor frequency-large numbers of peripheral blood mononuclear cell can be transduced to express modified and functionally improved tumor-specific T-cell receptors. 4 At the same time recent reports on severe adverse events after adoptive immunotherapy 7 and preclinical animal models showing significant toxicity after transferring TCR gene transferred peripheral blood mononuclear cell also emphasize the risks of T-cell immunotherapy and stress the need for meticulous preclinical evaluation including mathematical modeling. Mathematical modeling can help rationalize the design of either appropriate dose per patient, or alternatively determine exclusion criteria, for patients with large tumor burden in case large CTL (or TIL) dose is unavailable. In summary, mathematical modeling can help pick the right schedule for the right patient and thus hopefully improve treatment success.
